D-Cateslytin is an antimicrobial peptide that exhibits potent inhibition activity against Candida albicans ( MIC = 2.9 μM). D-Cateslytin can rapidly enter C. albicans, and shows no cytotoxicity to human gingival fibroblasts, and is stable in saliva. D-Cateslytin can be used for research on Candida albicans related diseases, such as oral candidosis [1].
In Vitro, D-Cateslytin (0-100 μg/mL, 24-72 h) shows no cytotoxicity to human gingival fibroblasts (HFG-1) after 72 hours for concentrations up to 100 μg/mL [1]. D-Cateslytin (100-123 μM, 24 h) remains stable in the supernatant of Candida albicans, and remains stable in human saliva[1].
References:
[1]. Dartevelle P, et al. D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections. Sci Rep. 2018 Jun 18;8(1):9235.
In Vitro, D-Cateslytin (0-100 μg/mL, 24-72 h) shows no cytotoxicity to human gingival fibroblasts (HFG-1) after 72 hours for concentrations up to 100 μg/mL [1]. D-Cateslytin (100-123 μM, 24 h) remains stable in the supernatant of Candida albicans, and remains stable in human saliva[1].
References:
[1]. Dartevelle P, et al. D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections. Sci Rep. 2018 Jun 18;8(1):9235.